



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/676,212	
	Filing Date	10/01/2003	
	First Named Inventor	Chen	
	Art Unit	1625	
	Examiner Name	To Be Assigned	
Total Number of Pages in This Submission	5	Attorney Docket Number	CD01613K

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	FORM 1449 (2 pages), 24 References, Return Post Card
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	THOMAS D. HOFFMAN, Reg. No. 28,221
Signature	
Date	March 24, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	THOMAS D. HOFFMAN, Reg. No. 28,221
Signature	
Date	March 24, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

The PTO did not receive the following listed item(s) Fee transmittal



Patent Case No. CD01613K

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Frank X. Chen, et al.

Application No.: 10/676,212

Filed: October 1, 2003

For: An Enantioselective Process

:

:

:

:

Group Art Unit: 1625

Examiner: To Be Assigned

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Schering-Plough Corp.
Patent Dept., K-6-1-1990
2000 Galloping Hill Rd
Kenilworth, NJ 07033

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants respectfully direct the Examiner's attention to the document(s) listed on the accompanying Forms PTO 1449. Applicants have listed publication dates on the attached Form PTO 1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not


to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in any prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed before the receipt of the first Office Action on the merits, and before the mailing date of a Final Rejection or Notice of Allowance.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO 1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

A handwritten signature in black ink, appearing to read "Thomas D. Hoffman", is written over the printed name.

THOMAS D. HOFFMAN
Attorney of Record for Applicants
Reg. No. 28, 221
Tel. No. (908) 298-5037
Fax No. (908) 298-5388

Sheet 1 of 2

FORM PTO-19 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: CD01613K	SERIAL NO.: 10/676,212
	APPLICANT: CHEN, et al.	
	FILING DATE: 10/01/2003	GROUP: 1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,372,909 B1	04/16/2002				
	AB	5,719,148	02/17/1998				
	AC	5,760,232	06/02/1998				
	AD	5,874,442	02/23/1999				
	AE	5,998,620	12/07/1999				
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	BA	W0 98/57958	12/23/1998					
	BB	W0 93/21176	10/28/1993					
	BC							
	BD							
	BE							


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Chemical Abstracts, Vol. 121, no. 7, Abstract No. 82181, (1994).
CB	Chemical Abstracts, Vol. 116, no. 19, Abstract No. 194813, (1992).
CC	Chemical Abstracts, Vol. 82, no. 17, Abstract No. 111993, (1975).
CD	Ahmad, S., et al. Inhibition of Pig Kidney L-Aromatic Amino Acid Decarboxylase by 2,3-Methano-m-tyrosines, <i>J. Med. Chem.</i> , Vol. 35, No. 8, (1992) pp. 1410-1417.
CE	Dolling, U., et al., Efficient Catalytic Assymmetric Alkylations 1. Enantioselective Synthesis of (+) - Indacrinone via Chiral Phase-Transfer Catalysis. <i>J. Am. Chem. Soc.</i> Vol 106, 1984, pp. 446 - 447.
CF	Evans, D.A., et al, Assymmetric Alkylation Reactions of Chiral Imide Enolates. A Practical Approach to the Enantioselective Synthesis of α -Substituted Carboxylic Acid Derivatives, <i>J. Med. Chem. Soc.</i> , Vol. 104, No. 6, (1982), pp. 1737 - 1738.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



	CC	Faber, W.S., <i>et al.</i> Catalytic Kinetic Resolution of 5-Alkoxy-2(5H)-Furanones, <i>Tetrahedron</i> , Vol. 50 No. 16, (1994), pp. 4775 – 4794.
	CH	Gauthier, S., <i>et al.</i> , (EM-800): A Highly Potent , Specific, and Orally Active Nonsteroidal Antiestrogen, <i>J. Med. Chem.</i> , Vol. 40, No. 14, (1997), pp. 2117 – 2122.
	CI	Gustafsson, H, <i>et al.</i> , Some New x-(Cyclopolymethylenepyrzazolyl-2) propionic Acids, Resolution of x(Cycloheptapyrazolyl-2) propionic Acid and Determination of its Absolute Configuration, <i>Acta. Chem. Scand. Ser. B</i> , Vol. B28, No. 9 (1974), pp. 1067-1073.
	CJ	Heaton, Steven B., <i>et al.</i> Chiral Arene Chromium Tricarbonyl Complexes as Enantoselective Catalysts: Highly Selective 1, 2 Alkyl Additions to Aldehydes <i>Tetrahedron letters</i> , Vol. 33, No. 13, (1992) pp. 1693 – 1696.
	CK	Kajiwara, Tadahiko, <i>et al.</i> , Stereoselective Synthesis of Ectocarpene and Its Antipode via Microbiological Asymmetric Hydrolysis, <i>Agric. Biol. Chem.</i> Vol. 45, No. 6 (1981) pp. 1461 – 1466.
	CL	Morgan, Brian, <i>et al.</i> , Enzymatic Kinetic Resolution of Piperidine Atropisomers: Synthesis of a Key Intermediate of the Farnesyl Protein Transferase Inhibitor, <i>SCH66336</i> , Vol. 65, No. 18 (2000), pp.5451 – 5459.
	CM	Njoroge, F. George, <i>et al.</i> , Synthesis of C-11 Methyl-Substituted Benzocycloheptapyridine Inhibitors of Farnesyl Protein Transferase; <i>Organic Letters</i> , Vol. 1, No. 9, (1999), pp. 1371 – 1373.
	CN	Njoroge, F. George, <i>et al.</i> , (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent; <i>J. Med. Chem.</i> , Vol. 41, No. 24, (1998), pp. 4890-4902.
	CO	Takaya, Y., <i>et al.</i> , Rhodium-catalyzed asymmetric 1, 4-addition of arylboron compounds generated in situ from aryl bromides, <i>Tetrahedron Letters</i> , Vol. 40 (1999) pp. 6957-6961.
	CP	Villani, F., <i>et al.</i> , Derivatives of 10, 11-Dihydro-5H-dibenso [a,d] cycloheptene and Related Compounds. 6. Aminoalkyl Derivatives of the Aza Isosteres, <i>Journal of Medicinal Chemistry</i> , Vol. 15, No. 7, (1972), pp. 750-754.
	CQ	Yamamura, S. <i>et al.</i> , Zinc Reductions of Keto-Groups to Methylene Groups, <i>J. Chem. Soc.</i> , (1968), pp. 2887 – 2889.
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>40681</p>		